The Molecular Pathology and Immunology Core of the University of Florida assists investigators participating in gene therapy projects aimed at reversing and/or preventing liver diseases, metabolic disorders, cystic fibrosis, alpha-1-antitrypsin (AAT) deficiency, and diabetes. Specifically, the Core supports these investigations by performing pathological and immunological analyses that characterize the host's immune system and cell/tissue responses to vectors and transgenes proposed for or currently used in experimental and preclinical studies. This goal will be accomplished by performance of three specific aims: 1) Determine the site(s) of viral vector and adult stem cell engraftment and toxicity in host tissues with respect to administration site, vector dose, and treatment duration. 2) Determine the potential beneficial effects of transgene expression in rodent models of 1-antitrypsin (AAT) deficiency, glycogen storage diseases, and other genetic and metabolic disorders. 3) Determine the immunogenicity of rAAV transgene products and capsid molecules administered to animals in studies investigating long-term therapeutic gene transfer and expression. Such studies are vital in order to evaluate whether rAAV therapy successfully ameliorates the pro-inflammatory environment within the site of administration and to determine the extent to which rAAV therapy induces acute inflammation or cytotoxicity or spreads hematogenously outside the site of administration. Centralization of the morphological studies, and standardization of the histopathological and toxicological determinants, enables rigorous assessment of host toxicity as a result of these treatment algorithms. Procedures include standard immunoassays, histopathology, histochemistry, immunohistochemistry, and FISH in mouse, rat, rabbit, primate, and cat models. In addition to providing a critical element for assurance of therapeutic safety, the Core should provide information that will enhance the feasibility and efficacy of gene delivery trials to the hepatocyte.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK058327-10
Application #
7918799
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
10
Fiscal Year
2009
Total Cost
$177,262
Indirect Cost
Name
University of Florida
Department
Type
DUNS #
969663814
City
Gainesville
State
FL
Country
United States
Zip Code
32611
Smith, Barbara K; Martin, A Daniel; Lawson, Lee Ann et al. (2017) Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity. Exp Neurol 287:216-224
Fu, Dongtao A; Campbell-Thompson, Martha (2017) Periodic Acid-Schiff Staining with Diastase. Methods Mol Biol 1639:145-149
Fu, Dongtao A; Campbell-Thompson, Martha (2017) Immunohistochemistry Staining for Human Alpha-1 Antitrypsin. Methods Mol Biol 1639:139-143
Ling, Chen; Yin, Zifei; Li, Jun et al. (2016) Strategies to generate high-titer, high-potency recombinant AAV3 serotype vectors. Mol Ther Methods Clin Dev 3:16029
Conlon, Thomas J; Mah, Cathryn S; Pacak, Christina A et al. (2016) Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors. Hum Gene Ther Clin Dev 27:152-159
Ling, Chen; Wang, Yuan; Lu, Yuan et al. (2015) The Adeno-Associated Virus Genome Packaging Puzzle. J Mol Genet Med 9:
Ling, Chen; Wang, Yuan; Lu, Yuan et al. (2015) Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in vitro and in murine hepatocytes in vivo. J Virol 89:952-61
Li, Baozheng; Ma, Wenqin; Ling, Chen et al. (2015) Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo. Hum Gene Ther Methods 26:211-20
Gruntman, Alisha M; Flotte, Terence R (2015) Progress with Recombinant Adeno-Associated Virus Vectors for Gene Therapy of Alpha-1 Antitrypsin Deficiency. Hum Gene Ther Methods 26:77-81
Nayak, Sushrusha; Doerfler, Phillip A; Porvasnik, Stacy L et al. (2014) Immune responses and hypercoagulation in ERT for Pompe disease are mutation and rhGAA dose dependent. PLoS One 9:e98336

Showing the most recent 10 out of 108 publications